糖皮质激素在重症新冠肺炎中的临床研究进展  

Advances in Clinical Studies of Glucocorticoids in Severe COVID-19

作　　者：王小燕 郑昕[1] Wang Xiaoyan;Zheng Xin(Department of Infectious Diseases,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China)

机构地区：[1]华中科技大学同济医学院附属协和医院感染科,武汉430022

出　　处：《华中科技大学学报（医学版）》2024年第4期563-568,共6页Acta Medicinae Universitatis Scientiae et Technologiae Huazhong

基　　金：国家自然科学基金资助项目(No.92169121)。

摘　　要：新型冠状病毒肺炎(COVID-19)是由SARS-CoV-2引起的急性呼吸道传染病,COVID-19的暴发流行对人民健康造成了很大影响。感染诱发的过度炎症反应所导致的细胞因子风暴被认为是新冠肺炎患者的主要致死原因,糖皮质激素因其强大的抗炎作用,已被广泛用于重症COVID-19患者。糖皮质激素曾用于病毒性肺炎的治疗,如传染性非典型肺炎(SARS)、中东呼吸综合征(MERS),但其对远期预后和死亡率的改善作用仍存在争议,且伴随较多的不良反应。因此临床上对糖皮质激素在COVID-19的治疗过程中的作用仍有较大的争议。该文对糖皮质激素治疗重症COVID-19的作用机制、时机、剂量、疗程、剂型选择等方面进行了综述,以期对临床治疗提供有价值的参考。Coronavirus disease 2019(COVID-19)is acute respiratory infectious disease due to SARS-CoV-2 infection,and the pandemic hit of COVID-19 has affected greatly on people's health.The cytokine storm caused by the infection-induced hyperinflammatory response is thought to be the primary cause of death in COVID-19 patients,and the glucocorticoids have been widely used in COVID-19 patients due to the powerful anti-inflammatory effect.Glucocorticoids have been used in the treatment of viral pneumonia,such as severe acute respiratory syndrome(SARS)and Middle East respiratory syndrome(MERS),but the improvement effects in long-term prognosis and mortality are still controversial,and are accompanied by many adverse effects.Therefore,the effect of glucocorticoids in the treatment of COVID-19 have been controversial.This article reviews the mechanism,timing,dose,duration and dosage form selection of glucocorticoids in the treatment of severe COVID-19,in order to provide a useful reference for clinical treatment.

关 键 词：重症新冠肺炎 激素 临床研究 

分 类 号：R563.12[医药卫生—呼吸系统]